Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 31;20(1):768.
doi: 10.3390/ijerph20010768.

The Association of IL-17 and PlGF/sENG Ratio in Pre-Eclampsia and Adverse Pregnancy Outcomes

Dorota Darmochwal-Kolarz  1 , Anita Chara  2
Affiliations

The Association of IL-17 and PlGF/sENG Ratio in Pre-Eclampsia and Adverse Pregnancy Outcomes

Dorota Darmochwal-Kolarz et al. Int J Environ Res Public Health. .

Abstract

The aim of the study was to assess the role of concentrations of interleukin-17 (IL-17), placental growth factor (PlGF) and soluble endoglin (sENG), as well as the PlGF/sENG ratio in pregnancy complicated by pre-eclampsia (PE) and normal pregnancy. The concentrations of IL-17, PlGF and sENG were measured with the use of immunoenzymatic methods. The concentrations of IL-17 were significantly higher in PE patients when compared to control patients. In the group of patients with PE, the levels of IL-17 positively correlated with systolic blood pressure. On the other hand, IL-17 negatively correlated with neonatal birth weight. The concentrations of PLGF were significantly lower and sENG significantly higher in studied patients when compared to controls. The PlGF/sENG ratio in the PE group was significantly lower when compared to healthy third trimester pregnant patients. In the study group, negative correlations were observed between the sENG concentrations and thrombocyte levels. The higher concentrations of IL-17 in PE could suggest its role as an inflammatory agent in the pathogenesis of the syndrome. Moreover, the negative correlation between IL-17 and a neonatal birth weight could suggest the role of the cytokine in the development of fetal growth restriction (FGR) associated with PE. It seems possible that IL-17 can be a useful marker of the risk of FGR in pregnancy complicated by PE. Furthermore, the results suggested the potential role of sENG and the PlGF/sENG ratio in the prediction of adverse outcomes such as HELLP syndrome and DIC.

Keywords: FGR (fetal growth restriction); PlGF/sENG ratio; endoglin (sENG); interleukin-17 (IL-17); placental growth factor (PlGF); pre-eclampsia; pregnancy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart showing the pregnant women from the control group that were included and excluded from the study.
Figure 2
Figure 2
The concentrations of interleukin-17 (IL-17) (pg/mL) in sera of patients with PE (n = 35) and in sera of women in the first, second and third trimesters of normal pregnancy (n = 45).
Figure 3
Figure 3
The concentrations of PlGF (pg/mL) in sera of patients with PE (n = 35) and in sera of women in the first, second and third trimesters of normal pregnancy (n = 45).
Figure 4
Figure 4
The concentrations of sENG (ng/mL) in sera of patients with PE (n = 35) and in sera of women in the first, second and third trimesters of normal pregnancy (n = 45).
Figure 5
Figure 5
The ratio of PlGF/sENG in sera of patients with PE (n = 35) and in sera of women in the first, second and third trimesters of normal pregnancy (n = 45).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Favel J.P. Hypertension during pregnancy. Epidemiology, definition. Presse Med. 2016;4982:30134–30138. - PubMed
    1. Poon L.C., Shennan A., Hyett J.A., Kapur A., Hadar E., Divakar H., McAuliffe F., da Silva Costa F., von Dadelszen P., McIntyre H.D., et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int. J. Gynaecol. Obstet. 2019;145((Suppl. S1)):1–33. doi: 10.1002/ijgo.12802. - DOI - PMC - PubMed
    1. Burton G.J., Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. Am. J. Obstet. Gynecol. 2018;218:S745–S761. doi: 10.1016/j.ajog.2017.11.577. - DOI - PubMed
    1. Spencer R., Rossi C., Lees M., Peebles D., Brocklehurst P., Martin J., Hansson S.R., Hecher K., Marsal K., Figueras F., et al. Achieving orphan designation for placental insufficiency: Annual incidence estimations in Europe. EVERREST Consortium. BJOG. 2019;126:1157–1167. doi: 10.1111/1471-0528.15590. - DOI - PubMed
    1. Opichka M.A., Rappelt M.W., Gutterman D.G., Grobe J.L., McIntosh J.J. Vascular Dysfunction in Preeclampsia. Cells. 2021;10:3055. doi: 10.3390/cells10113055. - DOI - PMC - PubMed

LinkOut - more resources